Nureca Limited
NSE: NURECA BSE: NURECA
Prev Close
288.9
Open Price
294
Volume
36,832
Today Low / High
286.05 / 305
52 WK Low / High
203.62 / 343
Range
285 - 315
Prev Close
288.6
Open Price
287.95
Volume
1,015
Today Low / High
285.2 / 306.45
52 WK Low / High
198 / 343.6
Range
285 - 315
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 300.35 (target range: 285 - 315), reflecting a change of 11.45 (3.96331%). On the BSE, it is listed at 300.3 (target range: 285 - 315), showing a change of 11.7 (4.05405%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Nureca Limited Graph
Nureca Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Nureca Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 300.35, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 300.30 | 303.30 | 272.97 - 333.63 |
| 306.31 | 245.04 - 367.57 | ||
| 309.31 | 216.52 - 402.10 | ||
| Bearish Scenario | 300.30 | 297.30 | 267.57 - 327.03 |
| 294.29 | 235.44 - 353.15 | ||
| 291.29 | 203.90 - 378.68 |
Overview of Nureca Limited
ISIN
INE0DSF01015
Industry
Medical - Devices
Vol.Avg
24,720
Market Cap
3,003,045,570
Last Dividend
0
Official Website
IPO Date
2021-02-25
DCF Diff
321.54
DCF
-21
Financial Ratios Every Investor Needs
Stock Dividend of NURECA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-02-24 | February 24, 22 | 3 | 3 | 2022-02-25 | 2022-03-14 | |
| 2021-09-21 | September 21, 21 | 2 | 2 | 2021-09-22 | 2021-10-28 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 109.66 Cr | 86.53 Cr | 23.13 Cr | 0.2110 | 0.00 Cr | 2.17 Cr | -9.55 Cr | 0.85 Cr | 0.85 | 4.90 Cr | 0.0077 |
| 2024-03-31 | 91.93 Cr | 60.79 Cr | 31.14 Cr | 0.3388 | 0.00 Cr | 2.21 Cr | -11.57 Cr | -1.79 Cr | -1.79 | 0.24 Cr | -0.0195 |
| 2023-03-31 | 111.32 Cr | 75.73 Cr | 35.59 Cr | 0.3197 | 0.00 Cr | 3.43 Cr | -16.25 Cr | -8.25 Cr | -8.25 | -7.90 Cr | -0.0741 |
| 2022-03-31 | 255.55 Cr | 132.96 Cr | 122.59 Cr | 0.4797 | 0.00 Cr | 5.22 Cr | 54.81 Cr | 44.96 Cr | 44.96 | 63.20 Cr | 0.1759 |
| 2021-03-31 | 213.45 Cr | 99.68 Cr | 113.78 Cr | 0.5330 | 0.00 Cr | 0.86 Cr | 62.21 Cr | 46.37 Cr | 62.04 | 64.23 Cr | 0.2173 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3.24 Cr | 209.98 Cr | 15.69 Cr | 194.2850 Cr | 4.97 Cr | 1.73 Cr | 39.92 Cr | 9.02 Cr | 0.00 Cr | 0.00 Cr | 3.82 Cr | 12.3990 Cr |
| 2024-03-31 | 14.06 Cr | 205.17 Cr | 12.05 Cr | 193.1110 Cr | 2.52 Cr | -11.55 Cr | 30.85 Cr | 5.08 Cr | 0.48 Cr | 0.00 Cr | -99.60 Cr | 9.2730 Cr |
| 2023-03-31 | 0.50 Cr | 206.58 Cr | 11.70 Cr | 194.8820 Cr | 3.33 Cr | 2.82 Cr | 34.48 Cr | 6.04 Cr | 0.33 Cr | 0.00 Cr | 7.24 Cr | 8.8830 Cr |
| 2022-03-31 | 8.25 Cr | 219.13 Cr | 15.93 Cr | 203.1970 Cr | 4.41 Cr | -3.84 Cr | 63.18 Cr | 7.80 Cr | 0.94 Cr | 0.00 Cr | 1.95 Cr | 12.2380 Cr |
| 2021-03-31 | 17.24 Cr | 185.75 Cr | 22.65 Cr | 163.0990 Cr | 3.89 Cr | -13.36 Cr | 36.78 Cr | 3.68 Cr | 0.44 Cr | 0.00 Cr | 0.10 Cr | 18.8670 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -19.0830 Cr | 8.4390 Cr | -0.1690 Cr | -23.4060 Cr | -10.8210 Cr | 3.2410 Cr | -4.3230 Cr | 1.3430 Cr | 1.8880 Cr | 0.0000 Cr | -9.0670 Cr |
| 2024-03-31 | -2.7120 Cr | 17.5760 Cr | -1.3030 Cr | -3.7980 Cr | 13.5580 Cr | 14.0620 Cr | -1.0860 Cr | -2.5440 Cr | -0.8210 Cr | 0.0000 Cr | 3.6260 Cr |
| 2023-03-31 | 10.2270 Cr | -16.4560 Cr | -1.5070 Cr | 9.8310 Cr | -7.7450 Cr | 0.5040 Cr | -0.3960 Cr | -10.7420 Cr | 0.0060 Cr | 0.0000 Cr | 28.7000 Cr |
| 2022-03-31 | 1.3990 Cr | -3.0890 Cr | -7.3020 Cr | -4.6000 Cr | -8.9930 Cr | 8.2490 Cr | -3.4040 Cr | 60.9810 Cr | -0.9220 Cr | -4.9930 Cr | -26.4010 Cr |
| 2021-03-31 | 34.8670 Cr | -110.0400 Cr | 92.3390 Cr | 34.1400 Cr | 17.1680 Cr | 17.2420 Cr | -0.7270 Cr | 62.3330 Cr | -8.1490 Cr | 0.0000 Cr | -20.3500 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 39.64 Cr | 30.06 Cr | 9.58 Cr | 0.2417 | 2.75 Cr | 3.73 Cr | 3.73 | 5.44 Cr | 0.0942 |
| 2025-09-30 | 37.74 Cr | 28.51 Cr | 9.23 Cr | 0.2445 | 2.74 Cr | 3.63 Cr | 3.63 | 5.59 Cr | 0.0961 |
| 2025-06-30 | 34.18 Cr | 22.18 Cr | 12.00 Cr | 0.3511 | -1.09 Cr | 0.81 Cr | 0.81 | 2.01 Cr | 0.0238 |
| 2025-03-31 | 31.74 Cr | 18.97 Cr | 12.77 Cr | 0.4023 | 0.68 Cr | 2.47 Cr | 2.47 | 3.19 Cr | 0.0777 |
| 2024-12-31 | 26.46 Cr | 16.53 Cr | 9.93 Cr | 0.3753 | -4.55 Cr | -2.80 Cr | -2.80 | -2.54 Cr | -0.1058 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.19 Cr | 7.55 Cr | 8.74 Cr | 8.30 Cr | 43.46 Cr | 192.93 Cr | 12.59 Cr | 224.66 Cr | 25.95 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 123.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -194.29 Cr |
| 2025-03-31 | 3.24 Cr | 70.39 Cr | 73.63 Cr | 5.15 Cr | 39.92 Cr | 189.95 Cr | 9.02 Cr | 209.98 Cr | 15.69 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 28.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -194.31 Cr |
| 2024-09-30 | 24.01 Cr | 4.27 Cr | 28.29 Cr | 10.02 Cr | 27.65 Cr | 193.82 Cr | 7.21 Cr | 214.96 Cr | 20.65 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 2.47 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -2.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -0.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Devices
No stocks found in this industry.
Key Executives
Gender: male
Year Born: 1983
Gender: male
Year Born: 1990
Gender: male
Year Born: 1980
Gender: male
Year Born: 1964
Gender: male
Year Born:
Gender: male
Year Born: 1986
Gender: female
Year Born: 1987
FAQs about Nureca Limited
The CEO is Aryan Goyal.
The current price is ₹300.35.
The range is ₹203.62-343.
The market capitalization is ₹300.30 crores.
The P/E ratio is 28.22.
The company operates in the Healthcare sector.
Overview of Nureca Limited (ISIN: INE0DSF01015) is a leading Medical - Devices in India. With a market capitalization of ₹300.30 crores and an average daily volume of 24,720 shares, it operates in the Medical - Devices. The company last declared a dividend of ₹0.